Insider Transactions in Q4 2025 at Teva Pharmaceutical Industries LTD (TEVA)
Insider Transaction List (Q4 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 16
2025
|
Roberto Mignone |
SELL
Open market or private sale
|
Indirect |
77,400
-17.39%
|
$2,322,000
$30.24 P/Share
|
|
Dec 16
2025
|
Amir Weiss Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
12,300
-68.52%
|
$369,000
$30.2 P/Share
|
|
Dec 09
2025
|
Mark Sabag |
SELL
Open market or private sale
|
Direct |
216,892
-54.52%
|
$6,072,976
$28.73 P/Share
|
|
Dec 09
2025
|
Mark Sabag |
BUY
Exercise of conversion of derivative security
|
Direct |
118,724
+30.56%
|
$2,137,032
$18.61 P/Share
|
|
Dec 09
2025
|
Richard Daniell Exec. VP, European Commercial |
SELL
Open market or private sale
|
Direct |
115,468
-70.47%
|
$3,233,104
$28.68 P/Share
|
|
Dec 09
2025
|
Richard Daniell Exec. VP, European Commercial |
BUY
Exercise of conversion of derivative security
|
Direct |
115,468
+24.34%
|
$1,962,956
$17.8 P/Share
|
|
Dec 02
2025
|
Chen Lichtenstein |
BUY
Exercise of conversion of derivative security
|
Direct |
4,804
+50.0%
|
-
|
|
Nov 26
2025
|
Roberto Mignone |
SELL
Open market or private sale
|
Indirect |
50,000
-10.1%
|
$1,300,000
$26.03 P/Share
|
|
Nov 20
2025
|
Christine Fox EVP, Head of U.S. Commercial |
SELL
Open market or private sale
|
Direct |
28,229
-30.73%
|
$677,496
$24.78 P/Share
|
|
Nov 20
2025
|
Christine Fox EVP, Head of U.S. Commercial |
BUY
Exercise of conversion of derivative security
|
Direct |
63,492
+40.87%
|
-
|
|
Nov 14
2025
|
Christine Fox EVP, Head of U.S. Commercial |
SELL
Open market or private sale
|
Direct |
30,000
-51.38%
|
$750,000
$25.11 P/Share
|
|
Nov 06
2025
|
Roberto Mignone |
SELL
Open market or private sale
|
Indirect |
200,000
-28.78%
|
$4,800,000
$24.11 P/Share
|
|
Nov 06
2025
|
Amir Weiss Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
12,300
-40.66%
|
$295,200
$24.44 P/Share
|